Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.52 |
| ▸ | SLC34A1 | Q06495 | 9/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4756479 | 0.82 | ALKBH1 (0.45) | PDE4DKDM4EMAPT | |
| SCHEMBL123446 | 0.82 | PDE4D (0.67) | PDE4DKDM4EMAPTPDE4BSLC34A1 | |
| SCHEMBL26659337 | 0.78 | PDE4D (0.66) | PDE4DKDM4EMAPTPDE4BSLC34A1 | |
| SCHEMBL5801416 | 0.77 | PDE4D (0.69) | PDE4DKDM4EMAPTPDE4BSLC34A1 | |
| SCHEMBL30900072 | 0.77 | PDE4D (0.68) | PDE4DKDM4EMAPTPDE4BSLC34A1 | |
| SCHEMBL20028517 | 0.76 | ALDH1A1 (0.51) | KDM4EMAPTSLC34A1ALDH1A1 | |
| SCHEMBL20074677 | 0.74 | SLC34A1 (0.59) | PDE4DPDE4BSLC34A1 | |
| SCHEMBL6070203 | 0.73 | PDE4D (0.63) | PDE4DKDM4EMAPTPDE4BSLC34A1 | |
| SCHEMBL10555219 | 0.73 | RAB9A (0.72) | KDM4EMAPTALDH1A1 | |
| SCHEMBL10917943 | 0.73 | RAB9A (0.52) | KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066674-B1 | OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AND THEIR USE AS ANTIVIRAL AGENTS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| US-7625905-B2 | Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1987036-A1 | HETERO-BYCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| US-20080103125-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
| WO-2007093520-A1 | HETERO-BYCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191335-A1 | 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191335-A1 | 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease | CCR5, CXCR1, CXCR3 | PDE4D 1266/4885KDM4E 2455/4885MAPT 3482/4885 |
| US-20080103125-A1 | Heterocylic antiviral compounds | CCR5, ACKR3, CXCR3 | PDE4D 1390/4885KDM4E 4084/4885MAPT 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.